Parecoxib reduces renal injury in an ischemia/reperfusion model in rats.
OBJECTIVE
To evaluate the effect of parecoxib (an NSAID) on renal function by measuring plasma NGAL (serum neutrophil gelatinase-associated lipocalin) levels in an induced-ischemia rat model.


METHODS
Forty male Wistar rats were randomly assigned to one of four groups: Ischemia (I), Ischemia/parecoxib (IP), No-ischemia (NI), and No-ischemia/parecoxib (NIP). Body weight, mean arterial pressure, heart rate, body temperature, NGAL levels, and renal histology were compared across groups.


RESULTS
The Ischemia (I) group, which did not receive parecoxib, showed the highest NGAL levels (p=0.001), while the IP group, which received the medication, had NGAL levels similar to those of the non-ischemic (NI and NIP) groups.


CONCLUSIONS
Parecoxib resulted in renal protection in this experimental model.
UNESP, Brazil.
José Pedro
JP
Calistro Neto
UNESP, Brazil.
Rômulo da Costa
Rda C
Torres
UNESP, Botucatu, SP, Brazil.
Giovanna Maria
GM
Gonçalves
UNESP, Botucatu, SP, Brazil.
Leopoldo Muniz da
LM
Silva
UNESP, Botucatu, SP, Brazil.
Maria Aparecida Custódio
MA
Domingues
UNESP, Botucatu, SP, Brazil.
Norma Sueli Pinheiro
NS
Módolo
UNESP, Botucatu, SP, Brazil.
Guilherme Antonio Moreira de
GA
Barros
D058186:Acute Kidney Injury / Q000473:pathology / Q000517:prevention & control*; D000209:Acute-Phase Proteins; D000818:Animals; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D007555:Isoxazoles / Q000627:therapeutic use*; D007668:Kidney / Q000098:blood supply* / Q000473:pathology; D000071068:Lipocalin-2; D054834:Lipocalins / Q000097:blood; D008297:Male; D011446:Prospective Studies; D011518:Proto-Oncogene Proteins / Q000097:blood; D011897:Random Allocation; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000517:prevention & control*; D015203:Reproducibility of Results; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
D000209:Acute-Phase Proteins; D015415:Biomarkers; D052246:Cyclooxygenase 2 Inhibitors; D007555:Isoxazoles; C097278:Lcn2 protein, rat; D000071068:Lipocalin-2; D054834:Lipocalins; D011518:Proto-Oncogene Proteins; C409945:parecoxib